Anticholinergic medication use and dementia: latest evidence and clinical implications.
Use of medications with anticholinergic activity is widespread in older adults. Several studies have highlighted that anticholinergic use may be associated with an increased risk of dementia. The objective of this narrative review is to describe and evaluate studies of anticholinergic medication use and dementia and provide practical suggestions for avoiding use of these medications in older adults. A comprehensive review of the literature, citations from recent reviews and the author's personal files was conducted. Four studies were found that evaluated anticholinergic use and dementia as the primary outcome. Three studies focused on overall anticholinergic medication use and reported a statistically significantly increased risk of Alzheimer's disease or dementia. In one study, dementia risk was primarily found with higher cumulative doses; people using anticholinergic medications at the minimum effective dose recommended for older adults for at least 3 years were at highest risk. In contrast, a study conducted in nursing-home residents with depression did not find that paroxetine [a highly anticholinergic selective serotonin reuptake inhibitor antidepressant, (SSRI)] increased risk for dementia compared with other SSRIs (without anticholinergic activity). Further study is needed to understand the mechanism by which anticholinergic medications may increase risk. In conclusion, there is evidence from three observational studies suggesting that anticholinergic medications may increase dementia risk. Given this potential risk and the myriad of other well-known adverse effects (i.e. constipation, blurred vision, urinary retention, and delirium) associated with anticholinergic medications, it is prudent for prescribers and older adults to minimize use of these medications and consider alternatives when possible.
School of Pharmacy, Health Sciences Building, H-361D Box 357630, University of Washington, Seattle, WA 98195-7630, USA.
Shelly L
SL
Gray
Division of Geriatrics, Department of Medicine, School of Medicine, Department of Pharmacy and Therapeutics, School of Pharmacy, and Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA; Geriatric Research, Education, and Clinical Center and Center for Health Equity Research and Promotion, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, USA.
Joseph T
JT
Hanlon
aged; antimuscarinics; dementia
J Am Geriatr Soc. 2015 Nov;63(11):2227-46
26446832
J Urol. 2015 May;193(5):1572-80
25623739
JAMA Neurol. 2016 Jun 1;73(6):721-32
27088965
Arch Gen Psychiatry. 2010 Apr;67(4):414-22
20368517
J Am Geriatr Soc. 2008 Jul;56(7):1333-41
18510583
J Alzheimers Dis. 2015;46(4):983-7
26402628
Psychopharmacology (Berl). 1992;107(2-3):437-41
1615141
Mol Imaging Biol. 2012 Dec;14(6):771-6
22476967
J Clin Psychopharmacol. 2012 Apr;32(2):273-7
22367653
BMJ. 2006 Feb 25;332(7539):455-9
16452102
J Geriatr Psychiatry Neurol. 1992 Apr-Jun;5(2):72-7
1317178
Psychiatr Serv. 2015 Dec 1;66(12):1333-40
26234334
Eur J Clin Pharmacol. 2013 Jul;69(7):1485-96
23529548
Alzheimers Dement. 2013 Jul;9(4):377-85
23183138
J Alzheimers Dis. 2012;30(2):253-61
22426015
Consult Pharm. 2012 Aug;27(8):564-82
22910177
J Am Geriatr Soc. 2012 Apr;60(4):616-31
22376048
JAMA Intern Med. 2015 Mar;175(3):401-7
25621434
Brain Res Brain Res Rev. 1992 Sep-Dec;17(3):215-26
1467811
Arch Intern Med. 2009 Jul 27;169(14):1317-24
19636034
Drugs Aging. 2014 Mar;31(3):185-92
24526293
Basic Clin Pharmacol Toxicol. 2014 Feb;114(2):151-9
24112192
J Gerontol A Biol Sci Med Sci. 2013 Mar;68(3):271-8
22982689
Eur Arch Psychiatry Clin Neurosci. 2010 Nov;260 Suppl 2:S111-5
20960005
BMJ Open. 2012 Sep 25;2(5):null
23015600
J Am Geriatr Soc. 2015 Dec;63(12):e8-e18
26447889
Psychopharmacology (Berl). 1990;100(2):243-50
2305013
Neurology. 2010 Jul 13;75(2):152-9
20625168
Consult Pharm. 2015 Apr;30(4):240-5
25893702
Clin Pharmacol Ther. 1990 Oct;48(4):337-9
2225695
Am J Geriatr Pharmacother. 2007 Sep;5(3):263-303
17996666
Ann Neurol. 2003 Aug;54(2):235-8
12891676